For example, the monoclonal antibody elotuzumab promotes cytotoxicity against MM cells via NK-mediated ADCC but also directly inhibits MM cell growth by inhibiting sSLAMF7–SLAMF7 interactions. Here, SLAMF7 is linked to Miyoshi myopathy.